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Authors' objectives
To assess the relationship of Lp(a) (lipoprotein (a)) concentration with the risk of major vascular and non-vascular outcomes.
Searching
MEDLINE and EMBASE were searched between January 1970 and March 2009. No language restrictions were used. Search terms were reported. References of retrieved articles and of previous reviews were searched and authors contacted in order to identify additional studies.
Study selection
Eligible studies were prospective cohort studies or analyses of nested case-control or case-cohort subsets that had baseline information on age, sex, Lp(a) and risk factors for cardiovascular disease. Studies used quantitative Lp(a) assay methods and recorded cause-specific mortality and/or major vascular morbidity using accepted criteria. Participants had no previous history of cardiovascular disease (myocardial infarction, angina or stroke) at baseline and had accrued more than one year of follow up. Primary outcomes of interest were non-fatal coronary heart disease (CHD), non-fatal stroke and cause-specific mortality (or at least fatal coronary heart disease and fatal stroke).
Studies originated from North America, Western Europe, Greece, Turkey, Australia and New Zealand. Forty seven per cent of participants were European and 50 per cent were North American. Participants' mean age at study entry was 57 years (standard deviation eight years). Forty eight per cent of participants were women and 52 per cent men.
A range of sources was used to identify participants. The method of patient preparation prior to blood sampling and storage of samples, and methods to assay samples, varied across the studies.
The authors stated neither how relevant studies were selected for the review nor how many reviewers performed the selection.
Assessment of study quality
Individual patient data were obtained and checked for internal consistency, which was confirmed by the collaborators.
Data extraction
Investigators of included trials were asked to provide individual patient data at baseline and subsequent follow ups in order to calculate hazard ratios and 95% confidence intervals (CI) for cohort studies and odds ratios and 95% CI for case controls.
Methods of synthesis
Hazard ratios and odds ratios were assumed to approximate the same relative risk and were described by the authors collectively as risk ratios. Risk ratios were pooled in both fixed-effects and random-effects models. Heterogeneity was assessed using the I 2 test. Sources of heterogeneity (such as racial group, study design and laboratory method) were investigated using subgroup analysis and meta-regression. Within-person variation and potential confounders were adjusted using conditional expectations of long-term average Lp(a) levels.
